Shimadzu Corporation, Eisai Co., Ltd., Oita University, and Usuki City Medical Association have demonstrated the utility of blood biomarkers in predicting the accumulation of amyloid beta (Aβ) (1) in ...
Zacks.com on MSN7d
SAGE's Dalzanemdor Fails to Meet Goal in Alzheimer's Disease StudyThe phase II LIGHTWAVE study evaluating Sage Therapeutics' dalzanemdor for treating cognitive issues due to Alzheimer's disease fails to meet the primary goal.
Alzheimer's treatment for adults with early symptomatic Alzheimer's disease (AD), which includes people with mild cognitive impairment (MCI) as well as people with the mild dementia stage of AD ...
The Ministry of Health, Labour and Welfare Japan has approved Kisunlaâ„¢ (donanemab-azbt, 350 mg/20 mL every four weeks injection for ...
On October 10, World Mental Health Day, Bell Let's Talk and Mental Health Research Canada (MHRC) will release a new report on the state of youth mental health in Canada at Toronto Metropolitan ...
News Medical on MSN24d
Blood microRNAs can predict conversion from mild cognitive impairment to dementia due to Alzheimer’s diseaseThe identification of AD at advanced stages leads to poor treatment outcomes. Thus, novel diagnostic techniques are required ...
Concomitant treatment for MCI (both pharmacological and non-pharmacological), as ... The metric used for validation and for selecting the appropriate classifier model is the area under the ROC curve ...
In a recent study, lean muscle mass appeared to be a protective factor against the development of Alzheimer's disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback